<SEC-DOCUMENT>0000950103-22-021164.txt : 20221219
<SEC-HEADER>0000950103-22-021164.hdr.sgml : 20221219
<ACCEPTANCE-DATETIME>20221219161958
ACCESSION NUMBER:		0000950103-22-021164
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221219
FILED AS OF DATE:		20221219
DATE AS OF CHANGE:		20221219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		221471321

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp185794_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of December 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Biop&ocirc;le</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Route de la Corniche 3B</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1066 Epalinges</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Switzerland</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Indicate by check
mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; width: 10%">&nbsp;&#9746;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; width: 10%">&nbsp;&#9744;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>INFORMATION CONTAINED
IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On December 19,
2022, ADC Therapeutics SA (the &ldquo;Company&rdquo;) announced that Jose &ldquo;Pepe&rdquo; Carmona has been appointed as the Company&rsquo;s
Chief Financial Officer. Jennifer Creel is leaving the Company to pursue other opportunities. Ms. Creel will serve as an advisor to the
Company for a period of time to facilitate a smooth transition. Below are the biographical and other information required by Item 6.A.
of Form 20-F with respect to Mr. Carmona:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Jose &ldquo;Pepe&rdquo;
Carmona was appointed as our Chief Financial Officer in December 2022. From October 2020 to November 2022, Mr. Carmona served as Chief
Financial Officer of Rubius Therapeutics, Inc. From May 2017 to September 2020, Mr. Carmona served as Chief Financial Officer of Radius
Health, Inc. Prior to that, Mr. Carmona served as the Chief Financial Officer of Innocoll Holdings plc and its predecessor entity, Innocoll
AG, and Chief Financial Officer of Alcon Europe, Middle East &amp; Africa, a division of Novartis AG, and served in numerous financial
management positions with increasing responsibility at Novartis. Mr. Carmona holds a B.S. in industrial civil engineering from Universidad
Tecnica Federico Santa Maria and an M.B.A. from Columbia Business School. There are no family relationships between Mr. Carmona or any
of our directors or executive officers.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The Company issued
a press release in connection with Mr. Carmona&rsquo;s appointment as Chief Financial Officer, which is attached hereto as Exhibit 99.1.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In addition, on
December 15, 2022, Robert A. Schmidt informed the Company of his resignation as the Company&rsquo;s Chief Accounting Officer, effective
December 30, 2022.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This Report on Form
6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration
Nos. 333-256807, 333-267293 and 333-267295) of ADC Therapeutics SA and to be a part thereof from the date on which this report is filed,
to the extent not superseded by documents or reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: December 19, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Peter J. Graham</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Peter J. Graham</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated December 19, 2022</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp185794_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="text-align: right; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>ADC Therapeutics Appoints Jose Carmona as Chief
Financial Officer</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LAUSANNE, Switzerland,
December 19, 2022</B> &ndash; ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose &ldquo;Pepe&rdquo; Carmona as
Chief Financial Officer (CFO), effective December 19, 2022. <FONT STYLE="color: #242424; background-color: white">He will serve on the
Company&rsquo;s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities.</FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;We warmly
welcome Pepe to ADC Therapeutics. As we enter the next phase of growth, I am confident that his extensive financial background, deep
capital markets experience and proven leadership in the pharmaceutical industry will help drive our corporate objectives and deliver
long-term value for shareholders,&rdquo; said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. &ldquo;We would like to sincerely
thank Jenn Creel for her many contributions to the Company, including building and leading the financial organization through multiple
stages of our evolution<FONT STYLE="color: #242424; background-color: white">.</FONT>&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Carmona <FONT STYLE="color: #242424; background-color: white">is
a seasoned CFO with over 20 years of leadership, commercial and partnership experience in the pharmaceutical industry, both in the U.S.
and internationally. He most recently served as CFO of Rubius Therapeutics where he was responsible for all financial functions as well
as business development, investor relations, information technology and procurement. Mr. Carmona helped capitalize the company through
both dilutive and non-dilutive financing vehicles and brought the organization from a research-stage company to a clinical-stage company.
Prior to joining Rubius, Mr. Carmona was the CFO of Radius Health and Innocoll. During his 12 years at Novartis, Mr. Carmona </FONT></FONT><FONT STYLE="font-size: 10pt; color: #242424">held
financial management positions with increasing responsibilities in various divisions and geographies, including CFO Alcon for Europe,
Middle East and Africa. He currently serves on the board of directors of HotSpot Therapeutics and Senda Biosciences.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #242424"><FONT STYLE="font-size: 10pt; background-color: white">&ldquo;I
am thrilled to join ADC Therapeutics, especially at this exciting point in the Company&rsquo;s evolution,&rdquo; said </FONT><FONT STYLE="font-size: 10pt">Mr.
Carmona. &ldquo;I believe the Company possesses great potential with its industry-leading expertise and a robust pipeline of innovative
assets. I welcome the opportunity to collaborate with my new colleagues and contribute to our mission of delivering transformative treatment
options to people with cancer.<FONT STYLE="background-color: white">&rdquo; </FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #242424"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About ADC Therapeutics</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation,
targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment
paradigm for patients with hematologic malignancies and solid tumors.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics&rsquo;
CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large
B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition
to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics
is based in Lausanne (Biop&ocirc;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,
please visit <FONT STYLE="color: #0563C1"><U>https://adctherapeutics.com/</U></FONT> and follow the Company on <FONT STYLE="color: #0563C1"><U>Twitter
</U></FONT>and <FONT STYLE="color: #0563C1"><U>LinkedIn</U></FONT>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">This press release
contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in
this press release, including statements regarding our future results of operations and financial position, business and commercialization
strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical
trials, regulatory submissions and approvals, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood
of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements
are based on our management&rsquo;s beliefs and assumptions and on information currently available to our management. Such statements
are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance
can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the
date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained
in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements
are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy
of any such forward-looking statements.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ZYNLONTA&reg; is a registered trademark
of ADC Therapeutics SA.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investors</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Eugenia Litz</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0; color: #0563C1"><FONT STYLE="font-size: 10pt"><U>Eugenia.Litz@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 3pt 0pt 0pt"><FONT STYLE="font-size: 10pt">+44 7879 627205</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Amanda Loshbaugh</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 3pt 0pt 0pt"><FONT STYLE="font-size: 10pt; color: #0563C1"><U>Amanda.Loshbaugh@adctherapeutics.com</U><BR>
</FONT><FONT STYLE="font-size: 10pt">+1 917-288-7023</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Media</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Mary Ann Ondish</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0; color: rgb(5,99,193)"><FONT STYLE="font-size: 10pt"><U>maryann.ondish@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 3pt 0pt 0pt"><FONT STYLE="font-size: 10pt">+1 914-552-4625</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != *<# 2(  A$! Q$!_\0
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MX9&W@_@<UW?A_P"*$%RZ6^LQ"!SP)X_N?B.HK USX9ZGIL3SV4BWL*\E5&'
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&1_UVT/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
